Show simple item record

dc.contributor.authorKapiriri, L
dc.contributor.authorLavery, JV
dc.contributor.authorSinger, PA
dc.contributor.authorMshinda, H
dc.contributor.authorBabiuk, L
dc.contributor.authorDaar, AS
dc.date.accessioned2020-12-21T02:12:36Z
dc.date.available2020-12-21T02:12:36Z
dc.date.issued2011-10-18
dc.identifierpii: 1471-2458-11-811
dc.identifier.citationKapiriri, L., Lavery, J. V., Singer, P. A., Mshinda, H., Babiuk, L. & Daar, A. S. (2011). The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries. BMC PUBLIC HEALTH, 11 (1), https://doi.org/10.1186/1471-2458-11-811.
dc.identifier.issn1471-2458
dc.identifier.urihttp://hdl.handle.net/11343/256827
dc.description.abstractBACKGROUND: Despite the increase in the number of clinical trials in low and middle income countries (LMICs), there has been little serious discussion of whether First in Human (FIH; phase 0 and phase 1) clinical trials should be conducted in LMICs, and if so, under what conditions. Based on our own experience, studies and consultations, this paper aims to stimulate debate on our contention that for products meant primarily for conditions most prevalent in LMICs, FIH trials should preferably be done first in those countries. DISCUSSION: There are scientific and pragmatic arguments that support conducting FIH trials in LMIC. Furthermore, the changing product-development and regulatory landscape, and the likelihood of secondary benefits such as capacity building for innovation and for research ethics support our argument. These arguments take into account the critical importance of protecting human subjects of research while developing capacity to undertake FIH trials. SUMMARY: While FIH trials have historically not been conducted in LMICs, the situation in some of these countries has changed. Hence, we have argued that FIH should be conducted in LMICs for products meant primarily for conditions that are most prevalent in those contexts; provided the necessary protections for human subjects are sufficient.
dc.languageEnglish
dc.publisherBMC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleThe case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries
dc.typeJournal Article
dc.identifier.doi10.1186/1471-2458-11-811
melbourne.affiliation.departmentSchool of Historical and Philosophical Studies
melbourne.source.titleBMC Public Health
melbourne.source.volume11
melbourne.source.issue1
dc.rights.licenseCC BY
melbourne.elementsid1232308
melbourne.contributor.authorSinger, Peter
dc.identifier.eissn1471-2458
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record